Active substanceDonepezilDonepezil
Similar drugsTo uncover
  • Alzepyl®
    pills inwards 
  • Arisept®
    pills inwards 
    Pfizer Inc.     USA
  • Dementis
    pills inwards 
  • Jasnal®
    pills inwards 
  • Dosage form: & nbspfilm-coated tablets
    Composition:

    Each tablet 5 mg, film-coated, contains:

    active substance: donepezil hydrochloride 5 mg;

    Excipients: lactose monohydrate 91.75 mg, corn starch 20.0 mg, microcrystalline cellulose 15.0 mg, giprolose 3.0 mg, magnesium stearate 0.25 mg, film shell opadray white YS-1R-18134-A (hypromellose, talc, macrogol, titanium dioxide (E 171)) 5.0 mg.

    Each tablet 10 mg, film-coated, contains:

    active substance: donepezil hydrochloride 10 mg;

    Excipients: lactose monohydrate 183.5 mg, corn starch 40.0 mg, cellulose microcrystalline mg, giprolose 6.0 mg, magnesium stearate 0.5 mg, film coat opadrai yellow YS-1R-12700-A (hypromellose, talc, macrogol, titanium dioxide (E 171), iron oxide dye yellow) 10.0 mg.

    Description:

    Dosage 5 mg: round, biconcave tablets, covered with a film shell of white color, with engraving "Aricept"on the one hand and" 5 "on the other. A single layer is visible on the cross-section. The core of the tablet is white.

    Dosage of 10 mg: Round, biconvex tablets, film-coated yellow color, with engraving "Aricept" on the one hand and "10" on the other. Two layers are visible on the cross-section. The core of the tablet is white.

    Pharmacotherapeutic group:Cholinesterase inhibitor
    ATX: & nbsp

    N.06.D.A.02   Donepezil

    Pharmacodynamics:

    Donepezil is a selective and reversible inhibitor of acetylcholinesterase, which is the predominant type of cholinesterase in the brain. Donepezil inhibits this enzyme is more than 1000 times stronger than butyrylcholinesterase contained mainly outside the central nervous system.

    After a single dose of donepezil in doses of 5 mg or 10 mg in the equilibrium state, the degree of inhibition of acetylcholinesterase activity measured in erythrocyte membranes after administration of the drug was 63.6% and 77.3%, respectively.

    The inhibition of acetylcholinesterase in erythrocytes under the influence of donepezil correlates with changes in the scores on the scale ADAS-cog (a scale of assessment of cognitive functions in Alzheimer's disease). The possible effect on neuropathological changes has not been studied.

    Pharmacokinetics:

    Suction

    Donepezil is well absorbed from the gastrointestinal tract; the relative bioavailability for oral administration is 100%. The maximum concentration (CmOh) donepezil in the plasma is achieved approximately 3-4 hours after ingestion. Plasma concentrations and area under the curve increase in proportion to the dose. The half-life of the plasma is approximately 70 hours, so the systematic use of single doses leads to a gradual achievement of the equilibrium state (usually within 2-3 weeks after the initiation of therapy). After reaching the equilibrium state, donepezil concentration in the plasma and the associated pharmacodynamic effects do not change significantly during the day. The intake of food does not affect the absorption of donepezil.

    As a result of repeated admission donepezil accumulates in the blood plasma and its content is increased 4-7 times; stable equilibrium concentration is achieved within 15 days. The volume of distribution in a state of stable equilibrium is 12 l / kg.

    Distribution

    Donepezil is approximately 95% bound to blood plasma proteins, mainly with albumins (about 75%) and alpha1acid glycoprotein.Information on binding to plasma proteins of its active metabolite 6-O-desmethyldonepezil is absent. Distribution donepezil in various tissues of the body has been studied insufficiently. It is assumed that donepezil and / or its metabolites may persist in the body for longer than 10 days.

    Metabolism and excretion

    Donepezil is metabolized in the liver and is excreted in the same way as its metabolites, mainly with kidneys: 79% of the dose is found in urine and 21% in feces. In the urine, donepezil. The main products of metabolized donepezil are compounds M1 and M2 (O-dealkylation and hydroxylation products), M11 and M12 (glucuronation products Ml and M2, respectively), M4 (hydrolysis product) and M6 (product N-oxidation). Reducing the concentration of donepezil in blood plasma occurs with a half-life (T1/2) and is about 70 hours.

    Sex, race and smoking have no significant effect on the concentration of donepezil in plasma.

    The average concentrations of donepezil in the plasma of patients correspond to those of healthy young volunteers.

    Indications:

    Symptomatic treatment of dementia of the Alzheimer's type of mild, moderate and severe.

    Contraindications:

    - Hypersensitivity to donepezil, other components of the drug, as well as to piperidine derivatives;

    - the efficacy and safety of donepezil in patients under the age of 18 years is not established;

    - deficiency of lactase, lactose intolerance, glucose-galactose malabsorption.

    Carefully:

    Cholinesterase inhibitors should be administered with caution to patients with obstructive pulmonary disease in the anamnesis (including bronchial asthma), with heart rhythm disorders (possibly vagotonic effect on heart rate, in particular bradycardia), with anesthesia, as well as patients with elevated risk of peptic ulcer development (for example, patients with a history of peptic ulcer disease or receiving concomitant therapy with nonsteroidal anti-inflammatory drugs), although there was no increase in the use of Arisept® I frequency of development of peptic ulcers or gastrointestinal bleeding (see "Special instructions").

    It is necessary to avoid simultaneous use of donepezil with other inhibitors of acetylcholinesterase, agonists or antagonists of the cholinergic system.

    Pregnancy and lactation:

    Adequate and controlled studies of safety of use in pregnancy have not been conducted, so the use of the drug in pregnancy is possible only if the intended benefit of therapy for the mother exceeds the potential risk to the fetus.

    Since data on the isolation of donepezil with breast milk of lactating women are not available, the use of the drug in breastfeeding should be avoided.

    Dosing and Administration:

    Inside, before going to bed, regardless of food intake.

    Adults

    Treatment begins with taking 5 mg once a day and continues for at least 4-6 weeks to reach equilibrium concentrations of donepezil and determine the early clinical effect of therapy. After 1 month, a single dose of Arisept® can be increased to 10 mg per day, which is the maximum recommended daily dose. Supportive therapy can be continued as long as the therapeutic effect remains, which should be evaluated regularly.

    Patients with impaired hepatic and renal function

    Violations of liver function of mild and moderate severity, as well as impaired renal function, do not significantly affect the clearance of donepezil, so this category of patients can be used in a similar manner.

    The use of the drug in patients with severe hepatic insufficiency has not been studied.

    Side effects:

    Alzheimer's disease of mild to moderate severity:

    More frequente (frequency ≥5% and twice as high as in the placebo group) - diarrhea, nausea, vomiting, muscle cramps, fatigue, insomnia.

    Frequent (frequency ≥ 5% and ≥ than in the placebo group) - headache, pain of different locations, accidents, colds, gastrointestinal disorders and dizziness.

    Rarely - fainting, bradycardia, sinoatrial and atrioventricular block. Laboratory indicators - a slight increase in the activity of the muscle isoform of creatine phosphokinase in the serum; There were no other significant deviations of laboratory parameters from the norm.

    Frequent - phenomena that developed in at least 1/100 patients;

    Infrequent - phenomena that developed in 1/100 - 1/1000 patients.

    These side effects were not necessarily associated with treatment with Aricept®, and in most cases in controlled studies their frequency was similar to that in the placebo group.

    Organism as a whole:

    Frequent: flu, pain in the chest, toothache;

    infrequent: fever, edema of the face, periorbital edema, hernia of the esophageal opening of the diaphragm, abscess, phlegmon, chills, general chills, sensation of head overflow, apathy.

    From the side of the cardiovascular system:

    Frequent: increased blood pressure, vasodilatation, atrial fibrillation, hot flushes, lowering blood pressure;

    infrequent: stenocardia, postural hypotension, myocardial infarction, AV blockade (first degree), chronic heart failure, arteritis, bradycardia, peripheral vascular disease, supraventricular tachycardia, deep vein thrombosis.

    From the digestive system:

    Frequent: fecal incontinence, gastrointestinal bleeding, bloating, epigastric pain;

    infrequent: eructation, gingivitis, increased appetite, flatulence, periodontal abscess, cholelithiasis, diverticulitis, salivation, dry mouth, herpes simplex, gastritis, irritable bowel syndrome, tongue edema, gastric discomfort, gastroenteritis, increased transaminase activity, hemorrhoids, intestinal obstruction, strong thirst, jaundice, melena, polydipsia, duodenal ulcer, stomach ulcer.

    From the endocrine system:

    infrequent: diabetes mellitus, goitre.

    On the part of the blood and lymphatic system:

    infrequent: anemia, thrombocytosis, thrombocytopenia, eosinophilia, erythropenia.

    From the side of metabolism and nutrition:

    Frequent: dehydration;

    infrequent: gout, hypokalemia, increased activity of creatine phosphokinase, hyperglycemia, weight gain, increased lactate dehydrogenase activity.

    From the musculoskeletal system:

    Frequent: bone fracture;

    infrequent: muscle weakness, myofascing.

    From the nervous system:

    Frequent: delirium, tremor, irritability, paresthesia, aggression, vertigo, ataxia, increased libido, anxiety, pathological cry, increased excitability, aphasia;

    infrequent: stroke, intracranial hemorrhage, transient ischemic attack, emotional lability, neuralgia, chills (localized), muscle spasm, dysphoria, abnormal gait, increased muscle tone, hypokinesia, neurodermatitis, numbness (localized), paranoia, dysarthria, dysphasia, hostility, decreased libido , melancholy, emotional fence, nystagmus, gait in large steps.

    From the respiratory system:

    frequent: shortness of breath, sore throat, bronchitis;

    infrequent: vomiting, the flow of mucus from the nasopharynx, pneumonia, hyperventilation, stagnation in the lungs, wheezing, hypoxia, pharyngitis, pleurisy, lung collapse, sleep apnea, snoring.

    From the skin and subcutaneous tissues:

    Frequent: itching, profuse sweating, urticaria;

    infrequent: dermatitis, erythema, skin discoloration, hyperkeratosis, alopecia, fungal dermatitis, shingles, hirsutism, skin striae, night sweats, skin ulcers.

    From the sense organs:

    Frequent: cataract, eye irritation, blurred vision;

    infrequent: dry eyes, glaucoma, earache, ringing in the ears, blepharitis, hearing loss, retinal hemorrhage, otitis externa, otitis media, unpleasant taste in the mouth, conjunctival hemorrhage, tinnitus, kinetosis, flies before the eyes.

    From the genitourinary system:

    frequent: urinary incontinence; nocturia;

    infrequent: dysuria, hematuria, urination, metrorrhagia, cystitis, enuresis, hyperplasia, prostate, pyelonephritis, inability to empty the bladder, fibroadenosis of the mammary glands, fibrocystic mastopathy, mastitis, pyuria, renal failure, vaginitis.

    Alzheimer's disease of severe severity:

    The most frequent (frequency not less than 5% and 2 times higher than in the placebo group, in most cases effects could be predicted based on the holinomimetic effect of donepezil): diarrhea, anorexia, vomiting, nausea and ecchymosis. These adverse events in most cases were transient, characterized by mild severity, and continued with continued donepezil therapy without the need for a dose change.

    Frequent - phenomena that developed in at least 1/100 patients;

    Infrequent - phenomena developing in 1 / 100-1 / 1000 patients.

    These side effects were not necessarily associated with treatment with Aricept®, and in most cases in controlled studies their frequency was similar to that in the placebo group.

    Organism as a whole:

    Frequent: abdominal pain, asthenia, fungal infection, influenza-like syndrome;

    infrequent: allergic reaction, phlegmon, malaise, sepsis, edema of the face, hernia.

    From the side of the cardiovascular system:

    frequent: lowering blood pressure, bradycardia, abnormal abnormalities of ECG parameters, heart failure; infrequent: myocardial infarction, angina pectoris, atrial fibrillation, chronic cardiac failure, peripheral vascular disease, supraventricular extrasystoles, ventricular extrasystoles, cardiomegaly.

    From the digestive system:

    frequent: constipation, gastroenteritis, stool incontinence, indigestion;

    infrequent: increased activity of gamma-glutamyltranspeptidase, gastritis, dysphagia, periodontitis, gastric ulcer, periodontal abscess, flatulence, pathological deviation of the results of functional hepatic tests, vomiting, esophagitis, rectal bleeding.

    From the endocrine system:

    infrequent: diabetes.

    On the part of the blood and lymphatic system:

    frequent: anemia; infrequent: leukocytosis.

    From the side of metabolism and nutrition:

    frequent: loss of mass, body, peripheral edema, increased lactate dehydrogenase activity, increased alkaline phosphatase activity;

    infrequent: hypercholesterolemia, hypokalemia, hypoglycemia, weight gain, hyperbilirubinemia, increased blood urea nitrogen concentration, B12-deficit anemia, cachexia, increased creatinine concentration, gout, hyponatremia, hypoproteinemia,iron deficiency anemia, increased activity of ALT and AST.

    From the musculoskeletal system:

    Frequent: arthritis;

    infrequent: arthrosis, bone fracture, arthralgia, lower extremity cramps, osteoporosis, myalgia.

    From the nervous system:

    Frequent: agitation, anxiety, tremor, convulsions, vagrancy, pathological gait;

    infrequent: apathy, vertigo, delirium, abnormal dreams, stroke, increased salivation, ataxia, euphoria, vasodilation, cerebral hemorrhage, cerebral infarction, cerebral ischemia, dementia, extrapyramidal syndrome, grand mal seizure, hemiplegia, increased muscle tone, hypokinesia.

    From the respiratory system:

    Frequent: pharyngitis, pneumonia, coughing, bronchitis;

    infrequent: shortness of breath, rhinitis, bronchospasm.

    From the skin and subcutaneous tissues:

    frequent: rash, skin ulcer, itching;

    infrequent: psoriasis, skin discoloration, shingles, dry skin, sweating, urticaria, vesicle-bullous rash.

    From the sense organs:

    infrequent: conjunctivitis, glaucoma, impaired vision, earache, tearing disorder.

    From the genitourinary system:

    Frequent: infection of the urinary tract, cystitis, hematuria, glucosuria;

    infrequent: vaginitis, dysuria, frequent urination, albuminuria.

    Side effects recorded in post-marketing research:

    Cases of hallucinations, aggressive behavior, seizures, hepatitis, stomach ulcers, duodenal ulcers and gastrointestinal bleeding.

    Overdose:

    Symptoms: cholinergic crisis (severe nausea, vomiting, excessive salivation, sweating, bradycardia, lowering of blood pressure, respiratory depression, collapse and convulsions). There may be an increase in muscle weakness, which, if affected by the respiratory muscles, can even lead to a fatal outcome.

    Treatment: symptomatic therapy. As an antidote for an overdose of Arisept®, tertiary anticholinergic agents can be used, in particular atropine in the initial dose of 1-2 mg IV, then the dose is selected depending on the effect. It is not known whether the donepezil and / or its metabolites in dialysis (hemodialysis, peritoneal dialysis or hemofiltration).

    Interaction:

    Clinical experience with Arisept® is limited, so the doctor prescribing the drug should take into account the risk of unknown interactions to date with other agents.

    Donepezil and / or its metabolic products do not inhibit the metabolism of theophylline, warfarin, cimetidine, digoxin, thioridazine, risperidone and sertraline. Simultaneous administration of digoxin, cimetidine, thioridazine, risperidone and sertraline does not affect donepezil metabolism

    In patients with Parkinson's disease who received combination therapy levodopa + [carbidopa], the use of donepezil for 21 days did not affect the concentration of these drugs in the blood. At the same time, there was no evidence of any effect on motor activity.

    In the metabolism of donepezil, the cytochrome P450 3A4 isoenzyme and, to a lesser extent, 2D6. Ketoconazole and quinidine, which are inhibitors of the isoenzyme CYP3A4 and 2D6, respectively, suppress the metabolism donepezil. Consequently, these and other isoenzyme inhibitors CYP3A4, such as itraconazole and erythromycin, and isoenzyme inhibitors CYP2D6, such as fluoxetine, can inhibit donepezil metabolism. In healthy volunteers ketoconazole increased mean concentrations of donepezil by approximately 30%. However, this action was not comparable with the action of ketoconazole on other substances metabolized with the participation of the isoenzyme CYP3A4, so it is unlikely to be of clinical significance.The use of donepezil does not affect the pharmacokinetics of ketoconazole.

    Inducers of microsomal liver enzymes, such as rifampicin, phenytoin, carbamazepine and alcohol, can cause a decrease in donepezil concentration. However, the degree of such inhibitory or inducing action is unknown, so use similar agents in combination with donepezil should be taken with caution.

    Donepezil can interfere with the action of drugs that have anticholinergic activity. In addition, with simultaneous application of donepezil may enhance the action of suxamethonium, other muscle relaxants or agonists of cholinergic receptors and beta-blockers that affect cardiac conduction, although the study in vitro showed that donepezil has a minimal effect on the hydrolysis of suxamethonium.

    With the simultaneous use of other cholinomimetics and quaternary anticholinergic drugs, such as glycopyrronium bromide, cases of atypical changes in blood pressure and heart rate are described.

    Special instructions:

    Treatment should be prescribed and conducted by a physician with experience in managing patients with Alzheimer's disease.The diagnosis should be made in accordance with generally accepted criteria (for example, DSM IV - Diagnostic and Statistical Manual on Mental Disorders of the Fourth Revision, ICD-10 - International Classification of Diseases of the 10th Revision).

    Supportive therapy can be continued as long as the therapeutic effect remains, which should be evaluated regularly. If the drug ceases to function, it should be discarded.

    After discontinuation of treatment there is a gradual decrease in the action of Arisept®, information on the "withdrawal" syndrome in the event of a sharp discontinuation of the drug is not available.

    Individual reaction to therapy donepezilom hydrochloride can not be predicted. The efficacy of donepezil in patients with other types of dementia, other than Alzheimer's dementia or other types of memory impairment (eg, age-related deterioration of cognitive function), has not been studied.

    Anesthesia: donepezil is an inhibitor of cholinesterase and can enhance muscle relaxation caused by depolarizing muscle relaxants during anesthesia.

    Cardiovascular diseases: Due to its pharmacological effect, cholinesterase inhibitors can have a vagotonic effect on the heart rate (in particular, cause bradycardia). The potential for such an action may be important for patients with sinus node weakness syndrome or other disorders of supraventricular conduction, such as sinoatrial or atrioventricular blockade.

    Gastrointestinal diseases: holinomimetiki can strengthen the secretion of acid in the stomach. At increased risk, developed ulcers, for example, in patients with a history of peptic ulcer disease or in patients receiving concomitant therapy with nonsteroidal anti-inflammatory drugs, during treatment it is necessary to monitor the relevant symptoms. However, in placebo-controlled studies donepezil there was no increase in the incidence of peptic ulcers or gastrointestinal bleeding.

    Neurological diseases: believe that holinomimetiki can cause generalized convulsions. However, the appearance of seizures can also be a manifestation of Alzheimer's disease.

    Lung diseases: taking into account the cholinomimetic effect of cholinesterase inhibitors, they should be administered with caution to patients with bronchial asthma or obstructive pulmonary disease in the anamnesis.

    Effect on the ability to drive transp. cf. and fur:Dementia Alzheimer's type itself can be accompanied by a violation of the ability to drive and use sophisticated technology. Besides, donepezil, mainly at the beginning of treatment or with increasing doses, can cause fatigue, dizziness and muscle cramps. The attending physician should decide whether a patient with dementia of the Alzheimer's type can drive a car or use complicated equipment during Arisept® treatment.
    Form release / dosage:

    Tablets, film-coated, 5 mg and 10 mg.

    Packaging:

    7, 14 or 15 tablets in a PVC / aluminum foil blister.

    1 blister for 7 tablets, 2 blisters for 14 tablets, 7 blisters for 14 tablets, 2 blisters for 15 tablets, 4 blisters for 15 tablets or 8 blisters for 15 tablets, along with instructions for use are placed in a cardboard box.

    Storage conditions:

    At a temperature of no higher than 30 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N016180 / 01
    Date of registration:09.12.2009 / 18.08.2015
    Expiration Date:Unlimited
    Date of cancellation:2017-07-27
    The owner of the registration certificate: Pfizer Inc. Pfizer Inc. USA
    Manufacturer: & nbsp
    Representation: & nbspPfizer H. Si. Pi. CorporationPfizer H. Si. Pi. Corporation
    Information update date: & nbsp12.09.2017
    Illustrated instructions
      Instructions
      Up